|1.||Kimura, Junji: 3 articles (05/2007 - 08/2002)|
|2.||Kondo, Masayo: 2 articles (05/2007 - 08/2002)|
|3.||Kawahara, Kazuo: 1 article (05/2007)|
|4.||Ushijima, Hideto: 1 article (05/2007)|
|5.||Morimoto, Katsumi: 1 article (05/2007)|
|6.||Miyajima, Masaharu: 1 article (05/2007)|
|7.||Tomino, Yasuhiko: 1 article (05/2007)|
|8.||Kaneda, Shinichi: 1 article (01/2007)|
|9.||Ogawa, Yumi: 1 article (01/2007)|
|10.||Harigai, Takashi: 1 article (01/2007)|
08/01/2002 - "In vitro, TRX-20 liposomes, but not plain PEG liposomes, avidly bound to and were readily internalized by highly metastatic tumor cells such as LM8G5 and ACHN cells, which express large amounts of CS on the cell surface. "
08/01/2002 - "LM8G5 tumor revealed that cisplatin-loaded TRX-20 liposomes were significantly more effective in reducing the local tumor growth than cisplatin-loaded plain PEG liposomes or free cisplatin. "
08/01/2002 - "Furthermore, the cisplatin-loaded TRX-20 liposomes markedly suppressed metastatic spreading of LM8G5 tumor cells to the liver, significantly increasing the survival time of the tumor-bearing mice. "
08/01/2002 - "When TRX-20 liposomes were loaded with cisplatin, they effectively killed the CS-expressing tumor cells in vitro, whereas cisplatin-PEG liposomes lacking TRX-20 were totally ineffective. "
01/01/2007 - "To evaluate the potential of using prednisolone phosphate (PSLP)-containing 3,5-dipentadecyloxybenzamidine hydrochloride (TRX-20) liposomes to treat rheumatoid arthritis (RA), we examined their ability to bind human fibroblast-like synovial (HFLS) cells and their effects in these cells. "
01/01/2007 - "Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: a novel approach to rheumatoid arthritis therapy."